|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | 亚太地区慢性乙型肝炎治疗共识(2012最新版)显示文摘自2008年至今,有大量关于慢性HBV感染的自然史和治疗的最新数据不断涌现。其中包括慢性HBV感染的无症状感染者,以社区为基础的队列研究,HBV基因型的作用,非药物诱导的自然HBV变异型毒株,无创性肝纤维化评估方法的应用,HBsAg定量在临床中的应用,更有效的新治疗药物和新治疗方案等等。来自亚太地区的专家审查和评估了相关数据,并共同商讨了近年来报道的最有意义的发现,基于此,对2008年版的亚太地区慢性乙型肝炎治疗共识进行修订,同时对2008年版治疗指南定义的关键词组进行了修订。修订后的指南包括以下几方面内容:一般治疗,肝纤维化评价适应证,何时开始治疗或停药,初始抗病毒治疗药物的选择,如何监测治疗中和治疗后的患者。关于特殊人群的治疗建议中包括了对妊娠妇女,已发生耐药,合并其他病毒感染,肝功能失代偿,接受免疫抑制治疗、化疗,肝移植或肝细胞癌患者的具体治疗建议。 | 廖运范 Jia-HorngKao Teerha Piratvisuth Henry Lik Yuen Chan Rong-Nan Chien Chun-Jen Liu Ed Gane Stephen Locarnini Seng-Gee Lim Kwang-Hyub Han Deepak Amarapurkar Graham Cooksley Wasim Jafri Rosmawati Mohamed Wan-Long Chuang Laurentius A.Lesmana Jose D.Sollano Dong-Jin Suh Masao Omata 刘颖 徐莹 李芸 黄祖雄 樊蓉 李小溪 吕国涛 周彬 孙剑 侯金林 | 2012 | 临床肝胆病杂志2012，28，8： | 182 |
| 2 | Telbivudine:A new treatment for chronic hepatitis B显示文摘世界范围的 3.5 亿个人被估计长期地感染肝炎 B。这些题目的 15%-40% 将在他们的生活期间开发肝硬化,肝失败或肝细胞癌。长期的肝炎 B 的治疗在最后十年优点上戏剧性地改善了到 nucleoside/nucleotide 类似物的来临和 pegylated 干扰素的使用。为长期的肝炎 B 治疗的同意的药包括:标准 interferon-alpha 2b, pegylated interferon-alpha 2a, lamivudine, adefovir dipivoxil,和 entecavir。不幸地,这些代理人不在所有病人是有效的并且与不同副作用被联系。干扰素有众多的副作用和类似物,很好被容忍,需要被用于延长时期的核甙或核苷酸,甚至无止境地。然而,与核甙延长了治疗或核苷酸类似物与抵抗的高率被联系。Telbivudine 是为在长期的肝炎 B 的治疗的使用的新奇、口头上地管理的核甙类似物。与另外的核甙类似物相对照, Telbivudine 没与 mitochondrial 毒性与哺乳动物的 DNA 聚合酶的抑制被联系。Telbivudine 与 lamivudine 相比与反应和优异病毒的抑制的显著地更高的率对肝炎 B 表明了有势力活动,标准疗法。Telbivudine 很好通常被容忍了,与低不利效果侧面,并且在它的有效剂量,没有限制剂量的毒性被观察了。Telbivudine 是之一最有势力为长期的肝炎 B 的抗病毒的代理人并且被食物及药品管理局在 2006 年末同意。 | Deepak N Amarapurkar | 2007 | World Journal of Gastroenterology2007，13，46： | 27 |
| 3 | Diagnosis of Crohn's disease in India where tuberculosis is widely prevalent显示文摘AIM:To define the parameters that positively predict diagnosis of Crohn's disease (CD) and differentiate it from gastrointestinal tuberculosis (GITB). METHODS:This prospective study over 3 years was carried out in the consecutive Indian patients with definite diagnosis of CD and equal numbers of patients with definite diagnosis of GITB. Demographic, clinical, laboratory, morphological and histological features were noted in all the patients. Serological tests such as p-ANCA, c-ANCA, IgA ASCA and IgG ASCA, were performed. Endoscopic biopsy and/or surgical tissue specimens were subjected to smear and culture for acid-fast bacilli (AFB) and tissue polymerase chain reaction for tuberculosis (TB PCR). Diagnosis of CD and GITB was based on the standard criteria. Data were analyzed using univariate Chi-square test and multiple logistic regression (MLR). RESULTS:The study is comprised of 26 patients with CD (age 36.6 ± 8.6 year, male:female, 16:10) and 26 patients with GITB (age 37.2 ± 9.6 year, male:female, 15:11). The following clinical variables between the two groups (CD vs TB) were significant in univariate analysis:duration of symptoms (58.1 ± 9.8 vs 7.2 ± 3.4 mo), diarrhoea (69.2% vs 34.6%), bleeding per rectum (30.7% vs 3.8%), fever (23.1% vs 69.2%), ascites (7.7% vs 34.6%) and extra-intestinal manifestations of inflammatory bowel disease (61.5% vs 23.1%). Of these, all except ascites and extra-colonic manifestations were found statistically significant by MLR. Accuracy of predicting CD was 84.62% based on the fever, bleeding P/R, diarrhoea and duration of symptoms while it was 63.4% when histology was reported as inflammatory bowel disease and 42.3% when there was recurrence of disease after surgery. Accuracy of predicting GITB was 73.1% when there was co-existing pulmonary lesions and/or abdominal lymphadenopathy;75% when tuberculosis was reported in histology;63.4% when granuloma was found in histology;82.6% when TB PCR was positive;and 61.5% when smear and/ or culture was positive for AFB. Serological test was not useful in differentiation of CD from GITB. Positivity rates for CD and GITB were:p-ANCA-3.8% and 3.8%, c-ANCA-3.8% and 0%, IgA ASCA-38.4% and 23.1%, and IgG ASCA-38.4% and 42.3%, respectively. CONCLUSION:Simple clinical parameters like fever, bleeding P/R, diarrhoea and duration of symptoms have the highest accuracy in differentiating CD from GITB. | Deepak N Amarapurkar Nikhil D Patel Priyamvada S Rane | 2008 | World Journal of Gastroenterology2008，14，5： | 24 |
| 4 | Changing spectrum of Budd-Chiari syndrome in India with special reference to non-surgical treatment显示文摘AIM: To evaluate patterns of obstruction, etiological spectrum and non-surgical treatment in patients with Budd-Chiari syndrome in India.METHODS: Forty-nine consecutive cases of Budd-Chiari syndrome (BCS) were prospectively evaluated. All patients with refractory ascites or deteriorating liver function were, depending on morphology of inferior vena cava (IVC) and/or hepatic vein (HV) obstruction, triaged for radiological intervention, in addition to anticoagulation therapy. Asymptomatic patients, patients with diuretic-responsive ascites and stable liver function, and patients unwilling for surgical intervention were treated symptomatically with anticoagulation.RESULTS: Mean duration of symptoms was 41.5 ± 11.2 (range = 1-240) mo. HV thrombosis (HVT) was present in 29 (59.1%), IVC thrombosis in eight (16.3%), membranous obstruction of IVC in two (4%) and both IVC-HV thrombosis in 10 (20.4%) cases. Of 35 cases tested for hypercoagulability, 27 (77.1%) were positive for one or more hypercoagulable states. Radiological intervention was technically successful in 37/38 (97.3%): IVC stenting in seven (18.9%), IVC balloon angioplasty in two (5.4%), combined IVC-HV stenting in two (5.4%), HV stenting in 11 (29.7%), transjugular intrahepatic portosystemic shunt (TIPS) in 13 (35.1%) and combined TIPS-IVC stenting in two (5.4%). Complications encountered in follow-up: death in five, re-stenosis of the stent in five (17.1%), hepatic encephalopathy in two and hepatocellular carcinoma in one patient. Of nine patients treated medically, two showed complete resolution of HVT.CONCLUSION: In our series, HVT was the predominant cause of BCS. In the last five years with the availability of sophisticated tests for hypercoagulability, etiologies weredefined in 85.7% of cases. Non-surgical management was successful in most cases. | Deepak N Amarapurkar Sundeep J Punamiya Nikhil D Patel | 2008 | World Journal of Gastroenterology2008，14，2： | 9 |
| 5 | Differentiation of Crohn’s disease from intestinal tuberculosis in India in 2010显示文摘Differentiating intestinal tuberculosis from Crohn’s disease (CD) is an important clinical challenge of considerable therapeutic significance. The problem is of greatest magnitude in countries where tuberculosis continues to be highly prevalent, and where the incidence of CD is increasing. The final clinical diagnosis is based on a combination of the clinical history with endoscopic studies, culture and polymerase chain reaction for Mycobacterium tuberculosis, biopsy pathology, radiological investigations and response to therapy. In a subset of patients, surgery is required and intraoperative findings with pathological study of the resected bowel provide a definitive diagnosis. Awareness of the parameters useful in distinguishing these two disorders in each of the different diagnostic modalities is crucial to accurate decision making. Newer techniques, such as capsule endoscopy, small bowel enteroscopy and immunological assays for Mycobacterium tuberculosis, have a role to play in the differentiation of intestinal tuberculosis and CD. This review presents currently available evidence regarding the usefulness and limitations of all these different modalities available for the evaluation of these two disorders. | Anna Benjamin Pulimood Deepak Narayan Amarapurkar Ujjala Ghoshal Mathew Phillip Cannanore Ganesh Pai Duvvur Nageshwar Reddy Birender Nagi Balakrishna Siddhartha Ramakrishna | 2011 | World Journal of Gastroenterology2011，17，4： | 8 |
| 6 | Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update显示文摘 | Yun-Fan Liaw Jia-Horng Kao Teerha Piratvisuth Henry Chan Rong-Nan Chien Chun-Jen Liu Ed Gane Stephen Locarnini Seng-Gee Lim Kwang-Hyub Han Deepak Amarapurkar Graham Cooksley Wasim Jafri Rosmawati Mohamed Jin-Lin Hou Wan-Long Chuang Laurentius Lesmana Jose | 2012 | Hepatology International2012，，3： | 6 |
| 7 | Consensus recommendations and review by an International Expert Panel on Interventions in Hepatocellular Carcinoma ( EPOIHCC )显示文摘 | Joong‐Won Park Deepak Amarapurkar Yee Chao Pei‐Jer Chen Jean‐Francois H. Geschwind Khean Lee Goh Kwang‐Hyub Han Masatoshi Kudo Han Chu Lee Rheun‐Chuan Lee Laurentius A. Lesmana Ho Yeong Lim Seung Woon Paik Ronnie T Poon Chee‐Kiat Tan Tawesak Tanwandee Gao | 2013 | Liver Int2013，，3： | 2 |
| 8 | Erratum to: Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update显示文摘 | Yun-Fan Liaw Jia-Horng Kao Teerha Piratvisuth Henry Lik Yuen Chan Rong-Nan Chien Chun-Jen Liu Ed Gane Stephen Locarnini Seng-Gee Lim Kwang-Hyub Han Deepak Amarapurkar Graham Cooksley Wasim Jafri Rosmawati Mohamed Jin-Lin Hou Wan-Long Chuang Laurentius A. | 2012 | Hepatology International2012，，4： | 2 |
| 9 | Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update显示文摘 | Yun-Fan Liaw Jia-Horng Kao Teerha Piratvisuth Henry Chan Rong-Nan Chien Chun-Jen Liu Ed Gane Stephen Locarnini Seng-Gee Lim Kwang-Hyub Han Deepak Amarapurkar Graham Cooksley Wasim Jafri Rosmawati Mohamed Jin-Lin Hou Wan-Long Chuang Laurentius Lesmana Jose | 2012 | Hepatology International2012，，3： | 1 |
| 10 | Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update显示文摘 | Yun-Fan Liaw Jia-Horng Kao Teerha Piratvisuth Henry Chan Rong-Nan Chien Chun-Jen Liu Ed Gane Stephen Locarnini Seng-Gee Lim Kwang-Hyub Han Deepak Amarapurkar Graham Cooksley Wasim Jafri Rosmawati Mohamed Jin-Lin Hou Wan-Long Chuang Laurentius Lesmana Jose | 2012 | Hepatology International2012，，3： | 1 |
| 11 | Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific Association for the Study of the Liver (APASL) 2014显示文摘 | Shiv Kumar Sarin Chandan Kumar Kedarisetty Zaigham Abbas Deepak Amarapurkar Chhagan Bihari Albert C. Chan Yogesh Kumar Chawla A. Kadir Dokmeci Hitendra Garg Hasmik Ghazinyan Saeed Hamid Dong Joon Kim Piyawat Komolmit Suman Lata Guan Huei Lee Laurentius A. | 2014 | Hepatology International2014，，4： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员